EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
JS Smolen, R Landewé, J Bijlsma… - Annals of the …, 2017 - ard.bmj.com
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …
Against Rheumatism (EULAR) RA management recommendations. A large international …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
JS Smolen, R Landewé, FC Breedveld… - Annals of the …, 2010 - ard.bmj.com
Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear
and consensual international recommendations on RA treatment are not available. In this …
and consensual international recommendations on RA treatment are not available. In this …
Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review
J Avouac, L Gossec, M Dougados - Annals of the rheumatic diseases, 2006 - ard.bmj.com
Objective: To evaluate the two generations of anti-cyclic citrullinated protein (CCP)
antibodies as a diagnostic marker of rheumatoid arthritis (RA) and as a predictor of future …
antibodies as a diagnostic marker of rheumatoid arthritis (RA) and as a predictor of future …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
JS Smolen, R Landewé, FC Breedveld… - Annals of the …, 2014 - ard.bmj.com
In this article, the 2010 European League against Rheumatism (EULAR) recommendations
for the management of rheumatoid arthritis (RA) with synthetic and biological disease …
for the management of rheumatoid arthritis (RA) with synthetic and biological disease …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
JS Smolen, RBM Landewé, JWJ Bijlsma… - Annals of the …, 2020 - ard.bmj.com
Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …
rheumatoid arthritis (RA) management recommendations to account for the most recent …
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician …
M Gianfrancesco, KL Hyrich, S Al-Adely… - Annals of the …, 2020 - ard.bmj.com
Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly
understood. The aim was to examine demographic and clinical factors associated with …
understood. The aim was to examine demographic and clinical factors associated with …
[HTML][HTML] European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
L Gossec, JS Smolen, S Ramiro, M De Wit… - Annals of the …, 2016 - ard.bmj.com
Background Since the publication of the European League Against Rheumatism
recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new …
recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new …
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported …
A Strangfeld, M Schäfer, MA Gianfrancesco… - Annals of the …, 2021 - ard.bmj.com
Objectives To determine factors associated with COVID-19-related death in people with
rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease …
rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease …
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
L Gossec, X Baraliakos, A Kerschbaumer… - Annals of the …, 2020 - ard.bmj.com
Objective To update the European League Against Rheumatism (EULAR) recommendations
for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the …
for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the …
[HTML][HTML] Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0
M Boers, JR Kirwan, G Wells, D Beaton… - Journal of clinical …, 2014 - Elsevier
Background Lack of standardization of outcome measures limits the usefulness of clinical
trial evidence to inform health care decisions. This can be addressed by agreeing on a …
trial evidence to inform health care decisions. This can be addressed by agreeing on a …